| 1 |
35008143 | Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. | 2022 Jan 10 |
2 |
| 2 |
35038825 | Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer. | 2022 Jan 17 |
1 |
| 3 |
35073148 | Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. | 2022 Mar 1 |
3 |
| 4 |
35083840 | Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis. | 2022 Mar |
3 |
| 5 |
35113748 | Marginal corneal infiltration following treatment for metastatic breast cancer with triple chemotherapy of Trastuzumab, Pertuzumab & Docetaxel. | 2022 Feb 3 |
3 |
| 6 |
33216943 | Annular atrophic lichen planus induced by anti-HER2 antibodies. | 2021 May |
1 |
| 7 |
33483889 | Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan. | 2021 Sep |
2 |
| 8 |
33685057 | [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis]. | 2021 Mar 1 |
3 |
| 9 |
33716633 | Trastuzumab, Pertuzumab, and Docetaxel as the First Line for HER-2-Positive Metastatic Breast Cancer among Arabs. | 2021 Feb |
3 |
| 10 |
33720069 | Changes in the therapeutic landscape of oesophago-gastric cancers. | 2021 Jul 1 |
1 |
| 11 |
33748921 | Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. | 2021 Jun |
2 |
| 12 |
33818899 | Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2-negative breast cancer patients treated with docetaxel. | 2021 May |
2 |
| 13 |
34053967 | Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203). | 2021 May |
1 |
| 14 |
34150608 | Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. | 2021 |
1 |
| 15 |
34165503 | Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial. | 2021 Sep 1 |
2 |
| 16 |
34215870 | A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). | 2021 Aug 30 |
1 |
| 17 |
34224826 | Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. | 2021 Oct |
1 |
| 18 |
34268925 | Cardiac safety of neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel/pertuzumab/trastuzumab for HER2-positive breast cancer patients. | 2021 May-Jun |
1 |
| 19 |
34296283 | Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). | 2021 Aug 30 |
1 |
| 20 |
34313026 | Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel. | 2021 Oct |
1 |
| 21 |
34352937 | Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. | 2021 Aug |
1 |
| 22 |
34533681 | Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. | 2021 Dec |
1 |
| 23 |
34533811 | Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis. | 2021 Sep |
1 |
| 24 |
34706686 | Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. | 2021 Oct 27 |
2 |
| 25 |
34737636 | Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy. | 2021 |
6 |
| 26 |
34872264 | Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China. | 2021 Nov |
3 |
| 27 |
34948097 | Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer. | 2021 Dec 10 |
1 |
| 28 |
31647503 | Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. | 2020 Mar 1 |
1 |
| 29 |
31805500 | A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. | 2020 Feb |
1 |
| 30 |
32171426 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. | 2020 Apr |
2 |
| 31 |
32194757 | Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients. | 2020 Mar |
3 |
| 32 |
32211111 | Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy. | 2020 |
2 |
| 33 |
32241871 | Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. | 2020 Apr |
1 |
| 34 |
32439744 | Fatal Clostridium septicum febrile neutropenia during adjuvant chemotherapy for early breast cancer. | 2020 May 20 |
1 |
| 35 |
32504284 | N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. | 2020 Aug |
1 |
| 36 |
32779037 | Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer. | 2020 Nov |
2 |
| 37 |
32850425 | Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives. | 2020 |
2 |
| 38 |
33046356 | Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER+ HER2- Breast Cancer: A Prospective Phase II Study. | 2020 Dec |
1 |
| 39 |
33099918 | Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer. | 2020 Jul-Aug |
3 |
| 40 |
33130751 | [Two Cases of Advanced HER2-Positive Locally Advanced Breast Cancer for Which Preoperative Chemotherapy with Pertuzumab, Trastuzumab, and Docetaxel Resulted in Good Response]. | 2020 Oct |
2 |
| 41 |
33205032 | Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study. | 2020 Nov |
1 |
| 42 |
33299647 | Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines. | 2020 Nov 15 |
1 |
| 43 |
33425535 | Therapy-Related Acute Myeloid Leukemia Following TCHP Chemotherapy in Two HER2+ Breast Cancer Patients. | 2020 Dec 7 |
1 |
| 44 |
33468917 | [A Case in Which Re-Administration of Pertuzumab/Trastuzumab with Eribulin Therapy Was Useful for Recurrent HER2 Breast Cancer]. | 2020 Dec |
1 |
| 45 |
29424297 | The Use of Immunotherapy to Treat Metastatic Breast Cancer. | 2019 |
1 |
| 46 |
30316083 | Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy. | 2019 Jan 1 |
1 |
| 47 |
30452336 | Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. | 2019 Jan 10 |
3 |
| 48 |
30744691 | Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. | 2019 Feb 11 |
1 |
| 49 |
31171748 | HER-2 aptamer-targeted Ecoflex® nanoparticles loaded with docetaxel promote breast cancer cells apoptosis and anti-metastatic effect. | 2019 Jun |
1 |
| 50 |
31470686 | Molecular Mechanisms of Antitumor Activity of PAMAM Dendrimer Conjugates with Anticancer Drugs and a Monoclonal Antibody. | 2019 Aug 29 |
2 |